BACKGROUND: Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models. OBJECTIVE: This review discusses the different mechanisms by which CB2 activation could induce therapeutic actions in MS. METHODS: Particular focus is given to the potential effects on inflammation/autoimmunity, remyelination and neuroprotection. CONCLUSION: This review discusses the importance of glial cells in sustaining these effects, as well as the putative secondary effects that would limit the use of CB2 agonists in the treatment of MS.
BACKGROUND:Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models. OBJECTIVE: This review discusses the different mechanisms by which CB2 activation could induce therapeutic actions in MS. METHODS: Particular focus is given to the potential effects on inflammation/autoimmunity, remyelination and neuroprotection. CONCLUSION: This review discusses the importance of glial cells in sustaining these effects, as well as the putative secondary effects that would limit the use of CB2 agonists in the treatment of MS.
Authors: Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero Journal: CNS Drugs Date: 2018-06 Impact factor: 5.749
Authors: María Gómez-Cañas; Gemma Navarro; Paula Morales; Dow P Hurst; Francisco J Carrillo-Salinas; Laura Lagartera; Ruth Pazos; Pilar Goya; Patricia H Reggio; Carmen Guaza; Rafael Franco; Javier Fernández-Ruiz; Nadine Jagerovic Journal: J Med Chem Date: 2016-07-06 Impact factor: 7.446
Authors: Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova Journal: J Neuroimmune Pharmacol Date: 2010-06-12 Impact factor: 4.147
Authors: Oliver P Keown; Timothy J Winterburn; Cherry L Wainwright; Sandra M Macrury; Ilene Neilson; Fiona Barrett; Stephen J Leslie; Ian L Megson Journal: Br J Clin Pharmacol Date: 2010-08 Impact factor: 4.335